Last updated 2026-07-26
- Raised $75M Series D led by SR One, Jul 2023
- Raised $57M Series C led by Pontifax, Aug 2020
- Raised $6M debt round led by Helsinn Investment Fund, Mar 2018
Total raised
$159.5M
Last: Undisclosed Round 2023-08
Stage
Series D
Founded
2011
Headcount
55
HQ
Philadelphia, United States
Sector
Health Tech & Life Sciences
About
Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies for patients with hard-to-treat cancers with unaddressed tumor mutations. The company utilizes a proprietary functional genomics platform called Foresight to identify and advance targeted drugs, including its lead asset, plixorafenib (FORE8394), a Class I/II BRAF inhibitor. While its global headquarters are in Philadelphia, USA, the company maintains discovery and functional genomics platform operations in Jerusalem, Israel.
Funding history · 7 rounds · $159.5M total
2023-07
D Round
$75.0M
★ SR One★ MedicxiOrbiMedWellington PartnersNovartis Venture FundSamsung Venture InvestmentCormorant Asset ManagementHBM Healthcare Investments
2020-08
C Round
$57.0M
★ PontifaxSR OneOrbiMedWellington ManagementNovartis Venture FundHBM Healthcare InvestmentsCormorant Asset Management
2018-03
Debt Financing
$6.0M
★ Helsinn Investment Fund★ Bio Capital Impact Fund★ Windham Venture Partners
2017-07
Grant
$5.0M
2016-05
B Round
$12.5M
★ OrbiMed★ Pontifax
2015-11
A Round
$2.0M
2013-06
Seed
$2.0M
Headcount over time
From 58 (2019-11) to 55 (2026-03) · -3 (-5%) · 36 points · source: Finder history + radar grounding
Q&A
- What is Fore Biotherapeutics' primary focus?
- Fore Biotherapeutics is a clinical-stage biotechnology company developing precision oncology therapies for patients with unaddressed tumor mutations.
- When did Fore Biotherapeutics raise its most recent Series D funding round?
- Fore Biotherapeutics raised a $67.4 million Series D round in July 2026. Lead investors included SR One and Medicxi.
- What was the amount and lead investors of Fore Biotherapeutics' Series D round in August 2023?
- In August 2023, Fore Biotherapeutics announced a $75 million Series D financing round. Lead investors included Medicxi and SR One.
- What is the status of FORE8394, Fore Biotherapeutics' lead asset?
- In February 2023, Fore Biotherapeutics announced the first patient dosed in a global Phase 2 trial evaluating FORE8394 in BRAF-mutated solid and brain tumors. Additionally, in March 2023, FORE8394 received FDA Orphan Drug Designation for the treatment of primary brain and CNS malignancies, and in September 2022, it received Fast Track Designation from the FDA for the treatment of cancers harboring BRAF Class 1 and Class 2 alterations.
- When did Fore Biotherapeutics appoint its current CEO?
- Fore Biotherapeutics appointed Matthew E. Ros as Chief Executive Officer in April 2022.
- What is the company's employee count?
- Fore Biotherapeutics has 51–200 employees.
- What was a significant corporate change for the company in early 2021?
- In February 2021, NovellusDx established Fore Biotherapeutics U.S. as its operating company in the United States and rebranded, also appointing Dieter Weinand as Chairman of the Board and Usama Malik as Chief Executive Officer and Director of the Board.
- What was the amount and lead investors of Fore Biotherapeutics' Series C funding round?
- Fore Biotherapeutics closed a $57 million Series C financing round in September 2020. Lead investors included Pontifax and OrbiMed.
Team · 2
Haim Gil-ad
Founder · Co-founder
Yoram Altschuler
Founder · Co-founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenesArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B
Highlights
1 Patents
Tags
personalizationoncologycancerpharmaceuticalsgenomicstargeted-therapypatientsartificial-intelligencedrug-discoverymachine-learningtherapeuticscancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | fore.bio |
|---|---|
| linkedin.com/company/18062584 |
Identifiers & details
| Former names | NovellusDx |
|---|---|
| Founded | 2011 |
| Employees (exact) | 55 |
| Offices | Philadelphia |
Radar intelligence
GitHub
| Top repos | Suiter-Final-Project, docker.github.io |
|---|
Web history (Wayback)
| Domain | fore.bio |
|---|
Certificate / subdomain footprint
| Subdomains | 7 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514625391 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2011-06-06 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 7 — other (1), people (2), violation (1), annual_report (3) |
| Registered address | האורן 4 קיסריה |
Recent registry events
| Date | Event |
|---|---|
| 2025-09-30 | עדכון כתובת ו/או מען דיגיטלי |
| 2025-10-21 | עדכון דירקטורים-הוספת דירקטור |
| 2025-10-21 | עדכון דירקטורים-הסרת דירקטור |
| 2025-09-21 | עדכון הפרה |
| 2025-09-21 | דו~ח שנתי-הסרת דירקטור |
| 2025-09-21 | דו~ח שנתי-הוספת דירקטור |
| 2025-09-21 | דו~ח שנתי-עדכון בעל תפקיד |